相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
Youri Hoogstrate et al.
NEURO-ONCOLOGY (2022)
Glioma-derived exosomes hijack the blood-brain barrier to facilitate nanocapsule delivery via LCN2
Chao Yang et al.
JOURNAL OF CONTROLLED RELEASE (2022)
Glycosylated modification of MUC1 maybe a new target to promote drug sensitivity and efficacy for breast cancer chemotherapy
Xiaomin Xi et al.
CELL DEATH & DISEASE (2022)
MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells
Masayuki Hagiwara et al.
CANCER RESEARCH (2021)
ANO1 regulates the maintenance of stemness in glioblastoma stem cells by stabilizing EGFRvIII
Hee-Jin Kim et al.
ONCOGENE (2021)
Proteasome inhibitor MG132 induces apoptosis in human osteosarcoma U2OS cells
Han Ki Lee et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2021)
MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells
Masayuki Hagiwara et al.
ONCOGENE (2021)
Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells
Jixing Zhao et al.
PHARMACOLOGICAL RESEARCH (2021)
MUC1-C Contributes to the Maintenance of Human Embryonic Stem Cells and Promotes Somatic Cell Reprogramming
Jeong-A Park et al.
STEM CELLS AND DEVELOPMENT (2021)
MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism
Appolinaire A. Olou et al.
ONCOGENE (2020)
Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways
Xiangqi Meng et al.
NATURE COMMUNICATIONS (2020)
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
Yota Yasumizu et al.
NATURE COMMUNICATIONS (2020)
EZH2: a novel target for cancer treatment
Ran Duan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Identification of long non-coding RNA HERC2P2 as a tumor suppressor in glioma
Chao Yang et al.
CARCINOGENESIS (2019)
Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2
Yu Ren et al.
CLINICAL EPIGENETICS (2019)
Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation
Anne Laugesen et al.
MOLECULAR CELL (2019)
Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma
Kai Huang et al.
ADVANCED SCIENCE (2019)
Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas
Qixue Wang et al.
AGING-US (2019)
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep
Yansheng Li et al.
THERANOSTICS (2019)
Bright Future for Novel Viral Glioblastoma Multiforme Therapy
David McCarthy et al.
WORLD NEUROSURGERY (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells
Hasan Rajabi et al.
ONCOGENE (2018)
Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway
Qixue Wang et al.
THERANOSTICS (2018)
Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2
Qun Chen et al.
CLINICAL CANCER RESEARCH (2018)
Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration
Sabrina Maisel et al.
Oncotarget (2017)
MUC1-C activates EZH2 expression and function in human cancer cells
Hasan Rajabi et al.
SCIENTIFIC REPORTS (2017)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Surendra K. Shukla et al.
CANCER CELL (2017)
Nuclear EGFRvIII resists hypoxic microenvironment induced apoptosis via recruiting ERK1/2 nuclear translocation
Hui Xie et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model
Jian-wei Wei et al.
CANCER LETTERS (2016)
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Sritama Nath et al.
TRENDS IN MOLECULAR MEDICINE (2014)
MG132, a proteasome inhibitor, induces apoptosis in tumor cells
Na Guo et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment
Gianmaria Liccardi et al.
CANCER RESEARCH (2011)
Analyzing real-time PCR data by the comparative C-T method
Thomas D. Schmittgen et al.
NATURE PROTOCOLS (2008)
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII
M. A. Stutz et al.
ONCOGENE (2008)
EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes
Michael V. Grandal et al.
CARCINOGENESIS (2007)
EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins
G. C. Davies et al.
ONCOGENE (2006)
The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
RB Luwor et al.
ONCOGENE (2004)
分享论文
